Allogeneic bone marrow-derived mesenchymal stem cells safety and tolerability in idiopathic Parkinson's disease

被引：0
|
作者：
Schiess, M. [1 ]
Suescun, J. [1 ]
Doursout, M. [1 ]
Adams, C. [1 ]
Green, C. [1 ]
Saltarrelli, J. [1 ]
Savitz, S. [1 ]
Ellmore, T. [1 ]
机构：
[1] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA
来源：
MOVEMENT DISORDERS | 2020年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
941
引用
收藏
页码：S416 / S418
页数：3
相关论文
共 50 条
  • [1] Safety and Tolerability of Bone Marrow-Derived Allogeneic Mesenchymal Stem Cells in Parkinson's Disease Patients
    Schiess, Mya C.
    Suescun, Jessika
    Doursout, Marie-Francoise
    Adams, Christopher
    Green, Charles
    Saltarrelli, Jerome G.
    Savitz, Sean
    Ellmore, Timothy
    ANNALS OF NEUROLOGY, 2020, 88 : S186 - S187
  • [2] Safety and Tolerability of Bone marrow-derived Allogeneic Mesenchymal Stem Cells in Parkinson's disease Patients
    Schiess, Mya
    Suescun, Jessika
    Doursout, Marie-Francoise
    Adams, Christopher
    Green, Charles
    Saltarrelli, Jerome
    Ellmore, Timothy
    NEUROLOGY, 2020, 94 (15)
  • [3] Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Safety in Idiopathic Parkinson's Disease
    Schiess, Mya
    Suescun, Jessika
    Doursout, Marie-Francoise
    Adams, Christopher
    Green, Charles
    Saltarrelli, Jerome G.
    Savitz, Sean
    Ellmore, Timothy M.
    MOVEMENT DISORDERS, 2021, 36 (08) : 1825 - 1834
  • [4] Safety of Bone marrow-derived Allogeneic Mesenchymal Stem Cells in Parkinson's Disease Patients
    Schiess, M.
    Suescun, J.
    Ellmore, T.
    Doursout, M. F.
    Furr-Stimming, E.
    Mei, Z.
    Gee, A.
    MOVEMENT DISORDERS, 2019, 34 : S82 - S84
  • [5] Preliminary Report on the Safety and Tolerability of Bone marrow-derived Allogeneic Mesenchymal Stem Cells infused intravenously in Parkinson's disease Patients
    Schiess, Mya
    Suescun, Jessika
    Ellmore, Timothy
    Doursout, Marie-Francoise
    Furr-Stimming, Erin
    Miao, Hongyu
    Mei, Zhuyong
    Gee, Adrian
    NEUROLOGY, 2019, 92 (15)
  • [6] Design and Baseline characteristic of Phase II clinical trial of allogeneic bone marrow-derived Mesenchymal Stem Cells as a disease-modifying therapy for idiopathic Parkinson's disease
    Schiess, Mya
    Ellmore, Timothy
    Shahnawaz, Mohammad
    Doursout, Marie-Francoise
    Adams, Christopher
    Tharp, Emily
    Suescun, Jessika
    NEUROLOGY, 2023, 100 (17)
  • [7] Preliminary Report on the Safety and Tolerability of Allogeneic Bone Marrow-derived Mesenchymal Stem Cells as a Disease-modifying Therapy for Parkinson's Disease: Phase IIa Double-blind, Randomized Controlled Trial
    Suescun, J.
    Ellmore, T.
    Adams, C.
    Thyne, V.
    Tharp, E.
    Chandra, S.
    Green, C.
    Shastri, R.
    Saltarrelli, J.
    Schiess, M.
    MOVEMENT DISORDERS, 2023, 38 : S53 - S53
  • [8] Bone marrow-derived mesenchymal stem cells
    Kemp, KC
    Hows, J
    Donaldson, C
    LEUKEMIA & LYMPHOMA, 2005, 46 (11) : 1531 - 1544
  • [9] Safety And Efficacy Of Allogeneic Bone Marrow-derived Mesenchymal Stem Cells In Neuromyelitis Optica Spectrum Disorder
    Kim, M.
    Nam, J.
    Lee, H.
    Lee, T.
    TISSUE ENGINEERING PART A, 2023, 29 (9-10)
  • [10] Intrathecal Transplantation of Autologous and Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Dogs
    Benavides, Felipe Perez
    Araujo Pinto, Giovana Boff
    Thomas Heckler, Marta Cristina
    Rodriguez Hurtado, Diana Milena
    Teixeira, Livia Ramos
    de Souza Monobe, Marina Mitie
    Machado, Gisele Fabrino
    de Melo, Guilherme Dias
    Rodriguez-Sanchez, Diego Noe
    Landim e Alvarenga, Fernanda da Cruz
    Amorim, Rogerio Martins
    CELL TRANSPLANTATION, 2021, 30
12345